Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry

Alan K.Y. Teoh, Helen E. Jo, Daniel C. Chambers, Karen Symons, Eugene H. Walters, Nicole S. Goh, Ian Glaspole, Wendy Cooper, Paul Reynolds, Yuben Moodley, Tamera J. Corte

Source: Eur Respir J, 55 (4) 1901855; 10.1183/13993003.01855-2019
Journal Issue: April
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Alan K.Y. Teoh, Helen E. Jo, Daniel C. Chambers, Karen Symons, Eugene H. Walters, Nicole S. Goh, Ian Glaspole, Wendy Cooper, Paul Reynolds, Yuben Moodley, Tamera J. Corte. Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry. Eur Respir J, 55 (4) 1901855; 10.1183/13993003.01855-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Elevated leukocyte count predicts survival in patients with idiopathic pulmonary fibrosis: analysis from the Swedish and Japanese cohorts
Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia
Year: 2021


Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020


Blood leukocyte levels as potential prognostic markers in IPF
Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia
Year: 2021


Increased monocyte count and red cell distribution width represent negative prognostic markers in patients with Idiopathic Pulmonary Fibrosis.
Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Year: 2020


Prognostic evaluation in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011

Dyspnoea: a prognostic marker for idiopathic pulmonary fibrosis
Source: Eur Respir J 2011; 37: 476
Year: 2011


Discovery and validation of peripheral blood gene expression profiles predictive of poor outcome and disease progression in idiopathic pulmonary fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014


Is blood eosinophil count a biomarker for chronic obstructive pulmonary disease in a real-world clinical setting? Predictive property and longitudinal stability in Japanese patients.
Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases
Year: 2021



Blood mitochondrial DNA as a biomarker of clinical outcomes in idiopathic pulmonary fibrosis
Source: Eur Respir J, 56 (5) 2001769; 10.1183/13993003.01769-2020
Year: 2020



Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015

Pulmonary expression of alternatively spliced tissue factor as a potential prognostic marker in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015

A simple prognostic tool for idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018




Genetic predictors of idiopathic pulmonary fibrosis (IPF) prognosis
Source: Eur Respir J 2006; 28: Suppl. 50, 830s
Year: 2006

Association between monocyte count and ILD progression in subjects with fibrosing ILDs: data from the INBUILD trial
Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Year: 2021



Prognostic value of modified classification based on lung function tests in idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2006; 28: Suppl. 50, 827s
Year: 2006

Different definitions of pulmonary hypertension in interstitial lung disease: a prognostic evaluation.
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020


Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017

Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone
Source: International Congress 2016 – Orphan diseases II
Year: 2016

Functional and prognostic significance of relationship between VC and TLC in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2005; 26: Suppl. 49, 334s
Year: 2005

Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013